Microscopic image of prostate cancer cells that metastasized to the lymph node of the patient.

Wilbert Zwart

Hormone-associated cancer

Hormonal therapies represent the first and most successful targeted therapies in cancer. In most breast and prostate cancers, hormonal therapy forms the very backbone of systemic treatment. However, resistance to therapy is common, and many patients relapse despite treatment.

Our group studies hormonal action in multiple tumor types. Our ultimate goal is to better understand hormonal signaling and elucidate therapy resistance in cancer, contributing to more personalized treatments, the identification of novel therapeutic options and minimizing over-treatment

More about this group

Our research

Our resources

Team members

Group leader

PhD student

PhD student

PhD student

PhD student

PhD student

Sebastian Gregoricchio

Postdoctoral fellow

Joshua Hodgson

Postdoctoral fellow

Angeliki-Maria Kefala

Technician

PhD student

PhD student

PhD student

Technician

Associate staff scientist

Kim van der Zande

PhD student

Yanis Zekri

Postdoctoral fellow

Wilbert Zwart and Andre Bergman about their colllaboration

Collaborations between lab and clinic are of vital importance for cancer research that can rapidly benefit patients. More and more cooperations between lab researchers and physicians are starting to form at the NKI. Wilbert Zwart and André Bergman are one of these duos.